Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom. more
Time Frame | BCYC | Sector | S&P500 |
---|---|---|---|
1-Week Return | -30.78% | -2.27% | -0.57% |
1-Month Return | -40.53% | -3.96% | 1.21% |
3-Month Return | -48.89% | -9.7% | 7.57% |
6-Month Return | -43.17% | -3.37% | 11.45% |
1-Year Return | -16.15% | 3.71% | 28.48% |
3-Year Return | -73.94% | 3.8% | 29.52% |
5-Year Return | 77.05% | 39.78% | 90.66% |
10-Year Return | 15.08% | 106.91% | 203.75% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 13.80M | 10.39M | 11.70M | 14.46M | 26.98M | [{"date":"2019-12-31","value":51.16,"profit":true},{"date":"2020-12-31","value":38.52,"profit":true},{"date":"2021-12-31","value":43.36,"profit":true},{"date":"2022-12-31","value":53.61,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 25.54M | 33.15M | 44.88M | 3.69M | 6.47M | [{"date":"2019-12-31","value":56.91,"profit":true},{"date":"2020-12-31","value":73.86,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":8.21,"profit":true},{"date":"2023-12-31","value":14.41,"profit":true}] |
Gross Profit | 13.80M | (22.76M) | (33.18M) | 10.78M | 20.51M | [{"date":"2019-12-31","value":67.29,"profit":true},{"date":"2020-12-31","value":-110.97,"profit":false},{"date":"2021-12-31","value":-161.8,"profit":false},{"date":"2022-12-31","value":52.54,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | 100.00% | (219.05%) | (283.69%) | 74.51% | 76.03% | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-219.05,"profit":false},{"date":"2021-12-31","value":-283.69,"profit":false},{"date":"2022-12-31","value":74.51,"profit":true},{"date":"2023-12-31","value":76.03,"profit":true}] |
Operating Expenses | 40.10M | 62.35M | 77.31M | 131.12M | 216.92M | [{"date":"2019-12-31","value":18.49,"profit":true},{"date":"2020-12-31","value":28.74,"profit":true},{"date":"2021-12-31","value":35.64,"profit":true},{"date":"2022-12-31","value":60.44,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (26.30M) | (51.96M) | (65.62M) | (116.65M) | (189.95M) | [{"date":"2019-12-31","value":-2629900000,"profit":false},{"date":"2020-12-31","value":-5196000000,"profit":false},{"date":"2021-12-31","value":-6561800000,"profit":false},{"date":"2022-12-31","value":-11665300000,"profit":false},{"date":"2023-12-31","value":-18994600000,"profit":false}] |
Total Non-Operating Income/Expense | (3.75M) | 452.00K | (5.73M) | 4.82M | 21.48M | [{"date":"2019-12-31","value":-17.46,"profit":false},{"date":"2020-12-31","value":2.1,"profit":true},{"date":"2021-12-31","value":-26.67,"profit":false},{"date":"2022-12-31","value":22.46,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (30.86M) | (51.73M) | (68.48M) | (114.24M) | (179.21M) | [{"date":"2019-12-31","value":-3086200000,"profit":false},{"date":"2020-12-31","value":-5173400000,"profit":false},{"date":"2021-12-31","value":-6848200000,"profit":false},{"date":"2022-12-31","value":-11424100000,"profit":false},{"date":"2023-12-31","value":-17920700000,"profit":false}] |
Income Taxes | (254.00K) | (724.00K) | (1.66M) | (1.52M) | 1.46M | [{"date":"2019-12-31","value":-17.43,"profit":false},{"date":"2020-12-31","value":-49.69,"profit":false},{"date":"2021-12-31","value":-114.14,"profit":false},{"date":"2022-12-31","value":-104.6,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (30.61M) | (51.01M) | (66.82M) | (112.72M) | (180.66M) | [{"date":"2019-12-31","value":-3060800000,"profit":false},{"date":"2020-12-31","value":-5101000000,"profit":false},{"date":"2021-12-31","value":-6681900000,"profit":false},{"date":"2022-12-31","value":-11271700000,"profit":false},{"date":"2023-12-31","value":-18066400000,"profit":false}] |
Income From Continuous Operations | (30.61M) | (51.01M) | (66.82M) | (112.72M) | (180.66M) | [{"date":"2019-12-31","value":-3060800000,"profit":false},{"date":"2020-12-31","value":-5101000000,"profit":false},{"date":"2021-12-31","value":-6681900000,"profit":false},{"date":"2022-12-31","value":-11271700000,"profit":false},{"date":"2023-12-31","value":-18066400000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (30.61M) | (51.01M) | (66.82M) | (112.72M) | (180.66M) | [{"date":"2019-12-31","value":-3060800000,"profit":false},{"date":"2020-12-31","value":-5101000000,"profit":false},{"date":"2021-12-31","value":-6681900000,"profit":false},{"date":"2022-12-31","value":-11271700000,"profit":false},{"date":"2023-12-31","value":-18066400000,"profit":false}] |
EPS (Diluted) | (3.41) | (2.65) | (2.69) | (3.80) | (5.13) | [{"date":"2019-12-31","value":-341,"profit":false},{"date":"2020-12-31","value":-265,"profit":false},{"date":"2021-12-31","value":-269,"profit":false},{"date":"2022-12-31","value":-380,"profit":false},{"date":"2023-12-31","value":-513,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
BCYC | |
---|---|
Cash Ratio | 15.79 |
Current Ratio | 17.13 |
Quick Ratio | 18.16 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
BCYC | |
---|---|
ROA (LTM) | -15.02% |
ROE (LTM) | -26.67% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
BCYC | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.17 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.83 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
BCYC | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 39.47 |
P/B | 1.75 |
Price/FCF | NM |
EV/R | 15.62 |
EV/Ebitda | NM |
Bicycle Therapeutics Ltd (BCYC) share price today is $13.81
Yes, Indians can buy shares of Bicycle Therapeutics Ltd (BCYC) on Vested. To buy Bicycle Therapeutics Ltd from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in BCYC stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Bicycle Therapeutics Ltd (BCYC) via the Vested app. You can start investing in Bicycle Therapeutics Ltd (BCYC) with a minimum investment of $1.
You can invest in shares of Bicycle Therapeutics Ltd (BCYC) via Vested in three simple steps:
The 52-week high price of Bicycle Therapeutics Ltd (BCYC) is $28.67. The 52-week low price of Bicycle Therapeutics Ltd (BCYC) is $12.17.
The price-to-earnings (P/E) ratio of Bicycle Therapeutics Ltd (BCYC) is
The price-to-book (P/B) ratio of Bicycle Therapeutics Ltd (BCYC) is 1.75
The dividend yield of Bicycle Therapeutics Ltd (BCYC) is 0.00%
The market capitalization of Bicycle Therapeutics Ltd (BCYC) is $1.46B
The stock symbol (or ticker) of Bicycle Therapeutics Ltd is BCYC